Pilot Study of Feasibility and Safety of Personalized Autologous Cluster of Differentiation 8 (CD8+) T Cell Therapy Plus Anti-PD1Antibody in Advanced Solid Malignancies

Trial Profile

Pilot Study of Feasibility and Safety of Personalized Autologous Cluster of Differentiation 8 (CD8+) T Cell Therapy Plus Anti-PD1Antibody in Advanced Solid Malignancies

Not yet recruiting
Phase of Trial: Phase I

Latest Information Update: 24 Apr 2017

At a glance

  • Drugs Pembrolizumab (Primary) ; T cell replacement therapy (Primary) ; Cyclophosphamide; Interleukin-2
  • Indications Gastrointestinal cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 19 Apr 2017 Planned primary completion date changed from 1 Feb 2021 to 1 Aug 2021.
    • 19 Apr 2017 Planned initiation date changed from 1 Feb 2017 to 1 Aug 2017.
    • 14 Nov 2016 Planned primary completion date changed from 1 Oct 2020 to 1 Feb 2021.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top